[ad_1]
SUZHOU, China, January 2, 2022 /PRNewswire/ – Kintor Pharmaceutical Limited (“Kintor Pharma,” Hong Kong Stock Exchange code: 9939), a clinical-stage biotechnology company that develops innovative small molecules and biological therapies, today announced that it will provide for the first time in its phase III clinical trial. The medicine KX-826 (“Pirutamide”) is in China For the treatment of male androgenetic alopecia (AGA) patients December 31, 2021. KX-826 is the first androgen receptor (AR) antagonist to enter the phase III clinical trial of AGA treatment. China And global.
exist November 24, 2021, Kintor Pharma announced, China’s The National Medical Products Administration (NMPA) approved the agreement for KX-826’s pivotal phase III study.
exist December 20, 2021, The KX-826 Phase III clinical trial main investigator kick-off meeting was successfully held. Peking University People’s Hospital and Huashan Hospital affiliated to Fudan University led the pilot project, with 26 hospitals participating.After successfully co-leading the Phase II clinical trial of KX-826 China For the treatment of AGA, Professor Zhang Jianzhong from Peking University People’s Hospital and Professor Yang Qinping from Huashan Hospital affiliated to Fudan University cooperated again and became…
The full story can be found on Benzinga.com
[ad_2]
Source link
